RecruitingAlzheimer's Disease (AD)
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Eligible age
50–85 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
Sponsor: Ludwig-Maximilians - University of Munich
You may qualify if…
- ✓ Diagnosis of amnestic MCI or AD dementia or clinical normal
- ✓ Able to provide written informed consent
- ✓ Unchanged pharmacotherapy within 4 days prior to the study specific assessments
- ✓ Fluent in German
You may not qualify if…
- ✕ Unable to give informed consent or has a legal guardian
- ✕ Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
- ✕ Clinically relevant depression
- ✕ Acute suicidality
- ✕ Current alcohol, drug or medication abuse
- ✕ History of severe traumatic brain injury within 3 months prior to inclusion
- ✕ Structural lesions of the basal ganglia or brain stem
- ✕ Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus
Source: ClinicalTrials.gov · NCT05059158 · last updated 2025-07-04